Loading...
Long-Lasting Immunity Against SARS-CoV-2: Dream or Reality?
Gussarow, Daniel Bonifacius, Agnes Cossmann, Anne Stankov, Metodi V Mausberg, Philip Tischer-Zimmermann, Sabine Gödecke, Nina Kalinke, Ulrich Behrens, Georg M N Blasczyk, Rainer
Gussarow, Daniel
Bonifacius, Agnes
Cossmann, Anne
Stankov, Metodi V
Mausberg, Philip
Tischer-Zimmermann, Sabine
Gödecke, Nina
Kalinke, Ulrich
Behrens, Georg M N
Blasczyk, Rainer
Citations
Altmetric:
Advisors
Editors
Other Contributors
Issue Date
2021-11-25
Submitted date
Files
Loading...
Open Access publication
Adobe PDF, 2.54 MB
Other Titles
Abstract
Since its declaration as a pandemic in March 2020, SARS-CoV-2 has infected more than 217 million people worldwide and despite mild disease in the majority of the cases, more than 4.5 million cases of COVID-19-associated death have been reported as of September 2021. The question whether recovery from COVID-19 results in prevention of reinfection can be answered with a "no" since cases of reinfections have been reported. The more important question is whether during SARS-CoV-2 infection, a protective immunity is built and maintained afterwards in a way which protects from possibly severe courses of disease in case of a reinfection. A similar question arises with respect to vaccination: as of September 2021, globally, more than 5.2 billion doses of vaccines have been administered. Therefore, it is of utmost importance to study the cellular and humoral immunity toward SARS-CoV-2 in a longitudinal manner. In this study, reconvalescent COVID-19 patients have been followed up for more than 1 year after SARS-CoV-2 infection to characterize in detail the long-term humoral as well as cellular immunity. Both SARS-CoV-2-specific T cells and antibodies could be detected for a period of more than 1 year after infection, indicating that the immune protection established during initial infection is maintained and might possibly protect from severe disease in case of reinfection or infection with novel emerging variants. Moreover, these data demonstrate the opportunity for immunotherapy of hospitalized COVID-19 patients via adoptive transfer of functional antiviral T cells isolated from reconvalescent individuals.
Citation
Front Med (Lausanne). 2021 Nov 25;8:770381. doi: 10.3389/fmed.2021.770381.
Publisher
Journal
PubMed ID
PubMed Central ID
Additional Links
Embedded video
Type
Article
Language
en
Description
Series/Report no.
ISSN
2296-858X
EISSN
ISBN
ISMN
Gov't Doc #
Sponsors
License
Attribution 4.0 International